Multiparameter computed tomography (CT) radiomics signature fusion-based model for the preoperative prediction of clear cell renal cell carcinoma nuclear grade: a multicenter development and external validation study
- PMID: 39429571
- PMCID: PMC11485359
- DOI: 10.21037/qims-24-35
Multiparameter computed tomography (CT) radiomics signature fusion-based model for the preoperative prediction of clear cell renal cell carcinoma nuclear grade: a multicenter development and external validation study
Abstract
Background: The preoperative prediction of the pathological nuclear grade of clear cell renal cell carcinoma (CCRCC) is crucial for clinical decision making. However, radiomics features from one or two computed tomography (CT) phases are required to predict the CCRCC grade, which reduces the predictive performance and generalizability of this method. We aimed to develop and externally validate a multiparameter CT radiomics-based model for predicting the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade of CCRCC.
Methods: A total of 500 CCRCC patients at The First, Second, and Yongchuan Hospitals of Chongqing Medical University between January 2016 and May 2022 were retrospectively enrolled in this study. The patients were divided into the training set (n=268), internal testing set (n=115), and two external testing sets (testing set 1, n=62; testing set 2, n=55). Radiomics features were extracted from multi-phase CT images, and radiomics signatures (RSs) were created by least absolute shrinkage and selection operator (LASSO) regression. In addition, a clinical model was developed. A combined model was also established that integrated the RSs with the clinical factors, and was visualized via a nomogram. The performance of the established model was assessed using area under the curve (AUC) values, a calibration curve analysis, and a decision curve analysis (DCA).
Results: Among the four RSs and the clinical model, the RS-Triphasic had the best predictive performance with AUCs of 0.88 [95% confidence interval (CI): 0.85-0.91] and 0.84 (95% CI: 0.74-0.95) in the training and testing sets, respectively, and 0.82 (95% CI: 0.72-0.93) and 0.82 (95% CI: 0.71-0.93) in external testing sets 1 and 2. Integrating the RS-Triphasic, RS-corticomedullary phase (CMP), RS-nephrographic phase (NP), RS-non-contrast phase (NCP) with the clinical risk factors, a combined model was established with AUCs of 0.92 (95% CI: 0.89-0.94), 0.86 (95% CI: 0.76-0.95), 0.84 (95% CI: 0.73-0.95), and 0.82 (95% CI: 0.70-0.94) for the training, internal testing, and external testing sets 1 and 2, respectively. The DCA indicated that the nomogram had a greater overall net benefit than the clinical and radiomics models.
Conclusions: The multiparameter CT RS fusion-based model had high accuracy in differentiating between high- and low-grade CCRCC preoperatively. Thus, it has great potential as a useful tool for personalized treatment planning and clinical decision making for CCRCC patients.
Keywords: Computed tomography (CT); clear cell renal cell carcinoma (CCRCC); multiparameter fusion radiomics model; pathological nuclear grade; radiomics.
2024 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-24-35/coif). The authors have no conflicts of interest to declare.
Figures
References
-
- Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R, O'Brien T, Panebianco V, Scelo G, Shuch B, van Poppel H, Blosser CD, Psutka SP. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol 2022;82:529-42. 10.1016/j.eururo.2022.08.019 - DOI - PubMed
-
- Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous